Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence

Highlights • GMPS is a prognostic biomarker and therapeutic target in PDAC.• GMPS knockdown suppresses PDAC proliferation in organoids, and PDX models.• GMPS deficiency triggers DNA damage, G1 arrest and cellular senescence.• GMPS knockdown activates the STING‑TBK1 innate immune pathway.

Yang-Yi Li, Zi-Feng Zhang, Ding-Ru Li et al. · 0 citations
Open access Sep 2026

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metasta...

S. Shi, Miao-Yan Wei, N. Du et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.